Purdue University

September ended and October began with an explosion of new venture capital available for biotech companies, raising expectations for VC fundraising by drug developers through the rest of 2024, especia

Lexeo Therapeutics Inc. became the 20th biopharma to launch an initial public offering in the US on 2 November when it sold 9.09 million shares at $11 each to gross $100m in its late-night public mar

Olema Pharmaceuticals, Inc. is not hurting for money after raising $139m in venture capital so far in 2020, but the company went public in the US on 18 November anyway to speed up clinical developmen

Nektar Therapeutics used its own expertise in targeting the interleukin-2 (IL-2) receptor for immuno-oncology to rapidly advance another novel compound with a different approach to the target, and n